The acquisition of Zoetis Inc.'s portfolio of medicated feed additives by Phibro Animal Health Corporation has been completed
Veröffentlicht am 4. Nov. 2024
The transaction was accomplished through the sale of the entire share capital of Zoetis Medolla Manufacturing S.r.l. and Zoetis Suzhou Manufacturing Co., Ltd. in favor of Phibro.
The closing for the acquisition of the entire portfolio of medicated feed additives of Zoetis Inc. by Phibro Animal Health Corporation for a consideration of approximately $350 million was finalized. The transaction was accomplished through the sale of the entire share capital of Zoetis Medolla Manufacturing S.r.l. and Zoetis Suzhou Manufacturing Co., Ltd. in favor of Phibro.
Chiomenti, alongside Kirkland & Ellis, advised Phibro on the Italian law aspects with a team led by partner Salvo Arena, managing associate Michelangelo Granato and associate Francesca Zimmardi. Zoetis was assisted by Wachtell, Lipton, Rosen & Katz.
